Emergingby GlyphNanobiotix prices an oversubscribed EUR 85M global offering
Gross proceeds reached about $100M after the over-allotment was exercised.
Nanotechnologysec.gov
Nanobiotix
Public companyFR1 field
Where it works
| Technology | ||
|---|---|---|
| NanotechnologyDevelops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900. | Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900. | nanobiotix.com |
Events
First randomized Phase 2 data for JNJ-1900 in stage 3 lung cancer
Johnson & Johnson presented the data at the 2026 European Lung Cancer Conference.
Nanotechnologysec.gov
European regulators reclassify NBTXR3 from device to medicinal product
The change aligns the nanoparticle's status with the US and other major markets.
Nanotechnologysec.gov
Nanobiotix amends its NBTXR3 licensing deal with Johnson & Johnson
The amendment strengthens Nanobiotix finances and extends cash visibility to mid-2026.
Nanotechnologysec.gov
FDA accepts protocol for Phase 2 NBTXR3 study in stage 3 lung cancer
Nanobiotix's radioenhancing nanoparticle moves into a randomized lung cancer trial.
Nanotechnologysec.gov
Funding
About
- Source
- nanobiotix.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 13, 2026
- Across Glyph
- Nanobiotix on Companies
Nanobiotix
Joined in Nanotechnology. Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900.
Nanobiotix
Added in Nanotechnology. Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900.